Compare AbCellera Biologics Inc (ABCL) vs Southwest Airlines Co (LUV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Southwest Airlines Co — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Southwest Airlines Co trades at $48.55 (market cap $24.16B). The key difference: Southwest Airlines Co is far larger — about 10.3× AbCellera Biologics Inc's market cap, and Southwest Airlines Co pays a 1.46% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | LUV | |
|---|---|---|
Market Cap | $2.35B | $24.16B |
Sector | Health | Industrials |
52-Week High | $8.12 | $54.80 |
52-Week Low | $2.78 | $29.06 |
Enterprise Value | $1.99B | $27.23B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Southwest Airlines (LUV) trades at $49.43, down 1.63% today, with a bullish technical signal from moving averages. The company reported revenue of $28.06B in 2025, with a net income margin of 2.83%, and has beaten earnings estimates in two of the last three quarters. Recent news highlights sector optimism due to lower fuel costs and strong travel demand, with analyst consensus leaning toward a buy rating and a $52.47 price target.
The outlook for LUV is cautiously optimistic, supported by earnings growth potential and favorable industry trends, but risks include volatile fuel prices and competitive pressures. The stock presents a moderate opportunity for investors seeking exposure to the airline sector, with upside to the consensus target but sensitivity to macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
